These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 26546142)

  • 41. Extended-release ranolazine: critical evaluation of its use in stable angina.
    Truffa AA; Newby LK; Melloni C
    Vasc Health Risk Manag; 2011; 7():535-9. PubMed ID: 21915171
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Glucose-Lowering Medications and Angina Burden in Patients with Stable Coronary Disease: results from the Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina (TERISA) Trial.
    Arnold SV; McGuire DK; Spertus JA; Tang F; Yue P; Inzucchi SE; Belardinelli L; Chaitman BR; Kosiborod M
    Am Heart J; 2015 Oct; 170(4):753-759.e2. PubMed ID: 26386799
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effectiveness of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina according to baseline hemoglobin A1c.
    Arnold SV; McGuire DK; Spertus JA; Li Y; Yue P; Ben-Yehuda O; Belardinelli L; Jones PG; Olmsted A; Chaitman BR; Kosiborod M
    Am Heart J; 2014 Oct; 168(4):457-465.e2. PubMed ID: 25262254
    [TBL] [Abstract][Full Text] [Related]  

  • 44. New oral nitric oxide-dependent medications for patients with coronary artery disease who have persistent angina pectoris.
    Blum A
    Coron Artery Dis; 2015 Dec; 26(8):639-41. PubMed ID: 26528628
    [No Abstract]   [Full Text] [Related]  

  • 45. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial.
    Stone PH; Gratsiansky NA; Blokhin A; Huang IZ; Meng L;
    J Am Coll Cardiol; 2006 Aug; 48(3):566-75. PubMed ID: 16875985
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of Ranolazine in Patients With Chronic Angina in Patients With and Without Percutaneous Coronary Intervention for Acute Coronary Syndrome: Observations From the MERLIN-TIMI 36 Trial.
    Gutierrez JA; Karwatowska-Prokopczuk E; Murphy SA; Belardinelli L; Farzaneh-Far R; Walker G; Morrow DA; Scirica BM
    Clin Cardiol; 2015 Aug; 38(8):469-75. PubMed ID: 26059896
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A multicentred randomised controlled trial of a primary care-based cognitive behavioural programme for low back pain. The Back Skills Training (BeST) trial.
    Lamb SE; Lall R; Hansen Z; Castelnuovo E; Withers EJ; Nichols V; Griffiths F; Potter R; Szczepura A; Underwood M;
    Health Technol Assess; 2010 Aug; 14(41):1-253, iii-iv. PubMed ID: 20807469
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Health economic evaluation of rivaroxaban in the treatment of patients with chronic coronary artery disease or peripheral artery disease.
    Cowie MR; Lamy A; Levy P; Mealing S; Millier A; Mernagh P; Cristeau O; Bowrin K; Briere JB
    Cardiovasc Res; 2020 Sep; 116(11):1918-1924. PubMed ID: 31807773
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ranolazine: a new option in the management of chronic stable angina.
    Dobesh PP; Trujillo TC
    Pharmacotherapy; 2007 Dec; 27(12):1659-76. PubMed ID: 18041887
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of ranolazine on left ventricular diastolic and systolic function in patients with chronic coronary disease and stable angina.
    Babalis D; Tritakis V; Floros G; Mouzarou A; Kafkas N; Bampali K; Mertzanos G
    Hellenic J Cardiol; 2015; 56(3):237-41. PubMed ID: 26021246
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of Ranolazine on Ischemic Myocardium IN Patients With Acute Cardiac Ischemia (RIMINI-Trial): A Randomized Controlled Pilot Trial.
    Schwemer TF; Radziwolek L; Deutscher N; Diermann N; Sehner S; Blankenberg S; Friedrich FW
    J Cardiovasc Pharmacol Ther; 2019 Jan; 24(1):62-69. PubMed ID: 29938533
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer.
    Sherman SK; Lange JJ; Dahdaleh FS; Rajeev R; Gamblin TC; Polite BN; Turaga KK
    JAMA Oncol; 2019 Feb; 5(2):236-242. PubMed ID: 30489611
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Ranolazine: a new approach to treating an old problem.
    Reddy BM; Weintraub HS; Schwartzbard AZ
    Tex Heart Inst J; 2010; 37(6):641-7. PubMed ID: 21224931
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Economic evaluation of trimetazidine in the management of chronic stable angina in Greece.
    Kourlaba G; Gourzoulidis G; Andrikopoulos G; Tsioufis K; Beletsi A; Maniadakis N
    BMC Health Serv Res; 2016 Sep; 16(1):520. PubMed ID: 27678370
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The usefulness of ranolazine for the treatment of refractory chronic stable angina pectoris as determined from a systematic review of randomized controlled trials.
    Banon D; Filion KB; Budlovsky T; Franck C; Eisenberg MJ
    Am J Cardiol; 2014 Mar; 113(6):1075-82. PubMed ID: 24462341
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The cost effectiveness of ivabradine in the treatment of chronic heart failure from the U.K. National Health Service perspective.
    Griffiths A; Paracha N; Davies A; Branscombe N; Cowie MR; Sculpher M
    Heart; 2014 Jul; 100(13):1031-6. PubMed ID: 24634022
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A randomised controlled trial to compare the safety, effectiveness and cost-effectiveness of doxycycline (200 mg/day) with that of oral prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid: the Bullous Pemphigoid Steroids and Tetracyclines (BLISTER) trial.
    Chalmers JR; Wojnarowska F; Kirtschig G; Mason J; Childs M; Whitham D; Harman K; Chapman A; Walton S; Schmidt E; Godec TR; Nunn AJ; Williams HC
    Health Technol Assess; 2017 Mar; 21(10):1-90. PubMed ID: 28406394
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Risk-based, 6-monthly and 24-monthly dental check-ups for adults: the INTERVAL three-arm RCT.
    Clarkson JE; Pitts NB; Goulao B; Boyers D; Ramsay CR; Floate R; Braid HJ; Fee PA; Ord FS; Worthington HV; van der Pol M; Young L; Freeman R; Gouick J; Humphris GM; Mitchell FE; McDonald AM; Norrie JD; Sim K; Douglas G; Ricketts D
    Health Technol Assess; 2020 Nov; 24(60):1-138. PubMed ID: 33215986
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction.
    McMurray JJV; Trueman D; Hancock E; Cowie MR; Briggs A; Taylor M; Mumby-Croft J; Woodcock F; Lacey M; Haroun R; Deschaseaux C
    Heart; 2018 Jun; 104(12):1006-1013. PubMed ID: 29269379
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Costs and clinical outcomes associated with use of ranolazine for treatment of angina.
    Phelps CE; Buysman EK; Gomez Rey G
    Clin Ther; 2012 Jun; 34(6):1395-1407.e4. PubMed ID: 22608105
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.